GELS (Gelteq) Ending Cash Position: $-0.22 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GELS Gelteq Ltd GELS
8 GF Score
Price $0.57
! 4 Warning Signs
View Full Analysis

What is Gelteq Ending Cash Position?

Gelteq GELS -0.99% 8 Ending Cash Position is $-0.22 Mil as of Dec. 2025. GuruFocus rates GELS with a GF Score™ of 8/100. The stock has 4 warning signs investors should review.

Gelteq's Ending Cash Position for the quarter that ended in Dec. 2025 was $-0.22 Mil.

Gelteq's quarterly Ending Cash Position declined from Dec. 2024 ($1.91 Mil) to Jun. 2025 ($0.23 Mil) and declined from Jun. 2025 ($0.23 Mil) to Dec. 2025 ($-0.22 Mil).

Gelteq's annual Ending Cash Position declined from Jun. 2023 ($0.27 Mil) to Jun. 2024 ($0.02 Mil) but then increased from Jun. 2024 ($0.02 Mil) to Jun. 2025 ($0.23 Mil).

Gelteq Ending Cash Position Related Terms

Gelteq Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Gelteq's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelteq Ending Cash Position Chart

Gelteq Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial 0.14 0.11 0.27 0.02 0.23

Gelteq Semi-Annual Data
Jun20 Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only 0.09 -0.07 1.91 0.23 -0.22
GELS
8GF Score
Gelteq Ltd GELS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gelteq Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gelteq's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.017+0.208
=0.23

Gelteq's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=-0.721+0.498
=-0.22

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $-0.22 Mil mean?
Gelteq (GELS) has a Ending Cash Position of $-0.22 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Gelteq and its competitors.
Is Gelteq's Ending Cash Position too high?
Gelteq's current Ending Cash Position is $-0.22 Mil. Overall, Gelteq has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Gelteq's Ending Cash Position compare to APUS and INM?
Gelteq's Ending Cash Position of $-0.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Gelteq and its competitors. Gelteq's current Ending Cash Position is $-0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelteq stock overvalued right now?
Gelteq (GELS) has a current Ending Cash Position of $-0.22 Mil. The current Ending Cash Position is $-0.22 Mil. Gelteq's overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Gelteq (GELS), the current Ending Cash Position is $-0.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelteq Business Description

Address 644 Chapel Street, Level 19, South Yarra, VIC, AUS, 3141
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis.
8GF Score

Get the complete analysis for GELS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price